Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: May 14, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Deep sclerectomy with bevacizumab and mitomycin C: a comparative study.

Nitin Anand1, Chunxiao Bong

  • 1Department of Ophthalmology, Calderdale & Huddersfield NHS Trust, Huddersfield Royal Infirmary, Huddersfield, UK.

Journal of Glaucoma
|February 23, 2013
PubMed
Summary

Subconjunctival Bevacizumab and Mitomycin C (MMC) show comparable efficacy and safety when used with deep sclerectomy (DS) for glaucoma. Both treatments effectively lower intraocular pressure with similar complication rates.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of visit schedule on estimated success rates in glaucoma surgical studies.

The British journal of ophthalmology·2026
Same author

Development and validation of the NIMHANS-NMHS-2 disability scale (NNDS).

Indian journal of psychiatry·2026
Same author

Psychometric properties and factor structure of the short form of the cyberchondria severity scale (CSS-12) amongst Indian adults.

Indian journal of psychiatry·2026
Same author

Lived experiences of individuals with cyberviolence: Understanding the nature of the dark side of social media use.

Industrial psychiatry journal·2025
Same author

Evaluating High Intraocular Pressure Criteria for Failure in Glaucoma Surgery: Impact on Estimated Success and Visual Field Rates.

American journal of ophthalmology·2025
Same author

Psychometric evaluation of smartphone addiction scale - short version (SAS-SV) among young adults of India.

Industrial psychiatry journal·2025

Area of Science:

  • Ophthalmology
  • Glaucoma Surgery
  • Vascular Endothelial Growth Factor Inhibitors

Background:

  • Deep sclerectomy (DS) is a surgical procedure to reduce intraocular pressure (IOP) in glaucoma.
  • Augmentation with intraoperative Mitomycin C (MMC) is a common practice to enhance surgical success.
  • Bevacizumab, a vascular endothelial growth factor inhibitor, is explored as an alternative adjunctive agent.

Purpose of the Study:

  • To compare the efficacy and safety of primary deep sclerectomy (DS) augmented with subconjunctival Bevacizumab versus intraoperative Mitomycin C (MMC).

Main Methods:

  • A retrospective, comparative case-control study included 75 eyes undergoing primary DS.
  • Patients were divided into two groups: 32 eyes received MMC and 43 eyes received Bevacizumab.

More Related Videos

Three-dimensional Angiogenesis Assay System using Co-culture Spheroids Formed by Endothelial Colony Forming Cells and Mesenchymal Stem Cells
09:24

Three-dimensional Angiogenesis Assay System using Co-culture Spheroids Formed by Endothelial Colony Forming Cells and Mesenchymal Stem Cells

Published on: September 18, 2019

Related Experiment Videos

Last Updated: May 14, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Three-dimensional Angiogenesis Assay System using Co-culture Spheroids Formed by Endothelial Colony Forming Cells and Mesenchymal Stem Cells
09:24

Three-dimensional Angiogenesis Assay System using Co-culture Spheroids Formed by Endothelial Colony Forming Cells and Mesenchymal Stem Cells

Published on: September 18, 2019

  • Complete success was defined as IOP <19 mm Hg with a 20% IOP reduction and no medications post-surgery.

    • Main Results:

    • No significant baseline differences were observed between the Bevacizumab and MMC groups.
    • Complete success rates at 1 and 2 years were similar between groups (e.g., 76.5% vs. 74.4% at 2 years).
    • Mean IOPs and complication rates were comparable, with no statistically significant differences observed.

    Conclusions:

    • Subconjunctival Bevacizumab is as efficacious as MMC in augmenting primary deep sclerectomy.
    • Bevacizumab augmentation does not appear to introduce additional side effects compared to MMC.